Skip to main content

Table 2 Evolution of clinical phenotypes of Behçet’s disease in Japan before correction for the follow-up period

From: Continuous evolution of clinical phenotype in 578 Japanese patients with Behçet’s disease: a retrospective observational study

  Group A pre 2000 (n = 323) Group B 2000–2007 (n = 164) Group C Post 2008 (n = 91) P
Observation time (years) 11.9 ± 9.3 6.3 ± 4.8 3.7 ± 2.2 <0.0001
Age at onset 36.9 ± 11.8 35.8 ± 13.1 37.6 ± 11.4 NS
Gender male, n (%) 134 (41.5) 76 (46.3) 37 (40.7) 0.80
HLA-B51, n (%) 107 (54.9) 48 (49.0) 16 (43.1) 0.061a
Complete type, n (%) 124 (38.4) 45 (27.4) 16 (17.6) <0.0001
Oral ulcer, n (%) 321 (99.4) 163 (99.4) 88 (96.7) 0.065
Genital ulcer, n (%) 246 (76.2) 116 (70.7) 55 (60.4) 0.0033
Eye involvement, n (%) 211 (65.3) 92 (56.1) 53 (58.2) 0.083
Skin involvement, n (%) 293 (90.7) 145 (88.4) 75 (82.4) 0.033
Arthritis, n (%) 166 (51.4) 87 (53.0) 48 (52.7) 0.75
Gastrointestinal involvement, n (%) 37 (11.5) 20 (12.2) 14 (16.5) 0.35
CNS involvement, n (%) 39 (12.1) 17 (10.4) 3 (3.3) 0.023
Vascular involvement, n (%) 26 (8.1) 17 (10.4) 3 (3.3) 0.35
  1. aNot all of the patients were typed for HLA-B51 positivity. Significant results are highlighted in bold font. CNS central nervous system, NS not significant